The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for ...
The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...
The U.S. Food and Drug Administration (FDA) has approved a drug to control seizures in dogs with idiopathic epilepsy, a type ...
Life Biosciences will test its gene therapy designed to partially reset a cell’s age and potentially reverse vision loss in patients with glaucoma and NAION.
The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
Summit Therapeutics SMMT announced that the FDA has accepted its biologics license application (BLA) seeking approval for ...
The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...
The FDA has approved the first dual-agent eye drop to treat presbyopia, a condition that causes gradual loss of near vision in adults.
A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...
The Phase I trial will recruit participants who have been diagnosed with non-arteritic anterior ischaemic optic neuropathy and open-angle glaucoma.
The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...
FDA approves KBroVet chewable tablets for managing canine idiopathic epilepsy.